APPROACH TO A 35-YEAR-OLD FEMALE WITH MELANOMA FOR 1 YEAR
This patient requires immediate comprehensive staging, surgical management with appropriate margins based on Breslow thickness, and consideration for sentinel lymph node biopsy and adjuvant therapy depending on stage.
Initial Clinical Assessment
Perform a thorough physical examination focusing on:
- The primary melanoma site for satellites or in-transit metastases
- Complete skin examination for additional suspicious lesions or second primary melanomas
- All regional lymph node basins for palpable adenopathy 1, 2
Histopathological Review
Ensure the pathology report includes these mandatory elements 1, 3:
- Breslow thickness in millimeters (most critical prognostic factor)
- Clark level of invasion
- Presence and extent of ulceration
- Surgical margin status
- Presence and extent of regression
- Mitotic rate
If the original biopsy was inadequate (partial biopsy, shave without depth assessment), rebiopsy is necessary 4.
Staging Workup Based on Breslow Thickness
For melanomas <1 mm thick (Stage 0/IA):
For melanomas ≥1 mm thick or with ulceration (Stage IB and higher):
- Consider baseline imaging: chest X-ray, CT chest/abdomen/pelvis 4, 5
- Ultrasound of regional lymph node basins 5
- Serum LDH if metastatic disease suspected 2
Surgical Management
Wide Local Excision Margins 1, 2, 3:
- In situ melanoma: 0.5 cm margins
- ≤1 mm Breslow: 1 cm margins
- 1-2 mm Breslow: 1-2 cm margins (1 cm acceptable)
- 2-4 mm Breslow: 2 cm margins
- >4 mm Breslow: 2-3 cm margins
Excision should extend to muscle fascia 2.
Sentinel Lymph Node Biopsy Decision
- All melanomas ≥1 mm Breslow thickness
- Melanomas 0.8-1.0 mm with ulceration or high mitotic rate
- Should be performed at experienced centers only
Key counseling points 2:
- SLNB provides staging information but has no proven therapeutic survival benefit
- Approximately 20% positivity rate for melanomas ≥1 mm
- 5% risk of technical failure
- Lower morbidity (5%) compared to complete lymph node dissection
If Sentinel Node Positive:
- Discuss completion lymph node dissection (though no overall survival benefit proven) 1, 2
- Consider adjuvant therapy (see below)
- Obtain additional staging imaging before lymphadenectomy 2
Adjuvant Therapy Considerations
For Stage IB and higher, particularly Stage III (node-positive) disease 4, 6:
The patient should be referred to medical oncology for discussion of:
- High-dose interferon alfa (improves disease-free survival but not overall survival; significant toxicity) 5
- Anti-PD-1 therapy (pembrolizumab, nivolumab) - newer option with improved outcomes
- BRAF/MEK inhibitors if BRAF V600 mutation present
- Clinical trial enrollment (preferred option) 7, 4
For Stage IA with favorable features:
- Observation is appropriate 4
Common Pitfalls to Avoid
Do not perform elective lymph node dissection without sentinel node mapping - it provides no survival benefit and increases morbidity 1, 2, 3
Do not use inadequate biopsy techniques - avoid partial biopsies, laser destruction, or electrocautery that prevent accurate Breslow depth measurement 3
Do not delay referral - patients with Stage IB or higher should be referred to a multidisciplinary melanoma team before definitive treatment 2
Do not use radiotherapy for primary melanoma with adequate surgical margins 3, 5
Do not perform routine imaging for thin melanomas (<1 mm) without high-risk features 1, 5
Follow-up Strategy
- Stage 0/IA: Annual full skin examinations for life 5
- Stage IB and higher: More frequent monitoring (every 3-6 months initially) with complete skin and lymph node examination 5
- Patient education on self-examination and sun protection
- No consensus exists for routine surveillance imaging in asymptomatic patients with localized disease 5
The one-year duration since diagnosis suggests this patient has already undergone initial treatment - verify completeness of excision margins and staging workup, and ensure appropriate surveillance is in place based on final pathologic stage.